Presentation
13 March 2024 An overview of 405nm violet-blue light as a potential pathogen inactivation technology for ex vivo platelet component safety from transfusion-transmitted infectious diseases
C. D. Atreya
Author Affiliations +
Abstract
Transfusion-transmitted infections (TTIs) is a major public health risk for ex vivo platelet concentrates (PCs) stored for transfusion. Current pathogen reduction technologies (PRTs) use chemicals and/or UV light, which are known to impede quality and efficacy of the treated products and potentiate adverse events in transfusion recipients, while mitigating TTIs. Relative to UV light, visible 405-nm violet-blue light is safer and recently studies were initiated to demonstrate the violet-blue light’s potential at a dose of 270 Jcm-2 for reducing microbial contamination in human plasma and platelets, while preserving the survival and recovery functions intact in a SCID mouse model.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
C. D. Atreya "An overview of 405nm violet-blue light as a potential pathogen inactivation technology for ex vivo platelet component safety from transfusion-transmitted infectious diseases", Proc. SPIE PC12822, Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2024, PC128220H (13 March 2024); https://doi.org/10.1117/12.3003271
Advertisement
Advertisement
KEYWORDS
Pathogens

Safety

Diseases and disorders

Plasma

Visible radiation

Ultraviolet radiation

Oxygen

Back to Top